BIO-TECHNE Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TECH in the last 30 days.
See all $TECH insider activity →Bio-Techne has extended the deadline for its $11.3B acquisition of Merck, refiling its intent to merge to allow the FTC more time for review. The life science tool company aims to complete the deal with the pharmaceutical giant.
Analysts covering Bio-Techne (TECH) have a consensus 'Hold' rating, with one 'Strong Buy' and one 'Strong Sell' among 15. This is less bullish than a month ago. Wells Fargo downgraded TECH to 'Equal Weight' with a $73 price target, above the mean target of $70.46. TECH trades above this average.
Avantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.
Over the past 7 days, alphai's AI scored 1 news story mentioning TECH (BIO-TECHNE Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TECH coverage spans earnings, mergers & acquisitions and financial news.
Potential closing of a large pharma‑life‑science merger.
Analyst downgrade may pressure the stock lower.
Earnings beat with little price movement suggests neutral short‑term outlook.
Phase-1 clearance is a positive step toward closing, but TECH still faces other jurisdictions and shareholder approval before deal completion.
Results beat estimates modestly, but the bigger trading driver is the ongoing Merck KGaA acquisition process plus margin softness in adjusted gross margin.
alphai scores every news story that mentions TECH with an AI model for sentiment and relevance, and aggregates insider trades from BIO-TECHNE Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio-Techne has extended the deadline for its $11.3B acquisition of Merck, refiling its intent to merge to allow the FTC more time for review. The life science tool company aims to complete the deal with the pharmaceutical giant.
1 min readAnalysts covering Bio-Techne (TECH) have a consensus 'Hold' rating, with one 'Strong Buy' and one 'Strong Sell' among 15. This is less bullish than a month ago. Wells Fargo downgraded TECH to 'Equal Weight' with a $73 price target, above the mean target of $70.46. TECH trades above this average.
1 min readAvantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.
3 min readGermany’s Bundeskartellamt cleared Merck’s planned acquisition of Bio-Techne in the first phase of merger control, saying the firms’ activities are largely complementary and overlaps do not raise major competition concerns. Merck offered $73 per Bio-Techne share, valuing it at about $11.3B (€9.9B). Remaining approvals are needed; closing expected late 2026 or early 2027.
4 min readBio-Techne (TECH) reported fiscal Q4 adjusted EPS of 52 cents, in line with the Zacks Consensus and down 1.9% year over year. Net sales were $321.2M, up 1% (3% organic) and 1.26% above estimates. Full-year adjusted EPS was $1.93. Shares rose to $72.23. TECH is also being acquired by Merck KGaA for $73/share.
6 min readBio-Techne (NASDAQ: TECH) corrected its dividend announcement. The shareholder of record date was misstated as Aug. 17, 2026 and is now Aug. 24, 2026. The company will pay a quarterly dividend of $0.08 per share for the quarter ended June 30, 2026, payable Aug. 28, 2026.
2 min readBio-Techne (NASDAQ:TECH) reported Q2 CY2026 sales of $321.2 million, up 1.3% year on year and 2% above Wall Street’s revenue estimate. Non-GAAP adjusted EPS was $0.52, near consensus and down from $0.53 a year earlier. Analysts expect full-year EPS to rise from $1.93 to $2.04.
4 min readBIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bio-Techne Releases Fourth Quarter Fiscal 2026 Results Minneapolis/August 12, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights ● Fourth quarter organ
6 min readConestoga Capital Advisors’ Q2 2026 investor letter says small-cap sentiment improved, citing strong Russell 2000 and Russell 2000 Growth results, though leadership was uneven. The letter highlights Bio-Techne (NASDAQ:TECH) as a performance contributor, noting its $72 close on Aug. 5, 2026, and a 43.57% 52-week gain. It says improving academic funding and large pharma strength helped, and that Bio-Techne agreed to be acquired by Merck KGaA (MRK-GR).
4 min readBio-Techne (TECH) is set to report fiscal Q4 2026 results on Aug. 5. In its prior quarter, adjusted EPS was 53 cents, missing the Zacks Consensus by 3.64%. Revenue is forecast at $317.2 million and EPS at 52 cents. The article also notes Merck KGaA agreed to acquire Bio-Techne for $73 per share.
6 min read
